LFB
30.9.2013 08:01:13 CEST | Business Wire | Pressemeddelelse
The biotechnologies company GamaMabs Pharma was launched and financed with LFB and BpiFrance‘s participation through Innobio fund next to IRDINov and iXO Private Equity in order to develop new cancer therapies. The company’s first product is a new monoclonal antibody targeting gynecological cancers, including ovarian cancer.
Ovarian cancer is responsible for over 50 000 deaths every year in Europe and the United States. It has a poor prognosis as it is often diagnosed at an advanced stage due to a lack of systematic screening. Increasing resistance to traditional chemotherapy treatments justifies research into targeted therapeutic solutions, such as monoclonal antibodies.
In collaboration with public partners (Inserm, Université de Montpellier; Institut du cancer de Montpellier), the LFB group has chosen an original antibody with strong cytotoxic activity from its propriety platform for the monoclonal antibody generations (EMABling®), to provide a new therapeutic approach to this pathology. The antibody 3C23K, for which LFB has obtained an exclusive operating license, has proven its effectiveness in experimental models of ovarian cancer.
Dr Jean-François Prost, former Scientific and medical director of the LFB group, and Stéphane Degove have joined forces to create GamaMabs Pharma and raise the necessary funds to develop this program.
GamaMabs Pharma benefits from an exclusive global sublicense from the
LFB group for the monoclonal antibody 3C23K and is supported by LFB
group’s EMABling® platform. In exchange for the agreed rights, LFB group
owns a minor participation in the capital of GamaMabs Pharma. Led by
BpiFrance through Innobio fund, the venture capital funds will
contribute up to 3.1 million euros to the deal.
This investment
will allow the validation of the therapeutic concept, in collaboration
with various regional centers specialized in the fight against cancer
and to prepare the first clinical trial.
Denis Soubeyran, Head of finance and strategy of LFB group has declared: “This contract provides every opportunity for the success of this very promising project, initiated by LFB group, for the treatment of ovarian cancer. Our capital contribution in GamaMabs Pharma, our implication in the project through our EmaBling® platform and the bioproduction capacity of our subsidiary LFB Biomanufacturing all demonstrate our interest and confidence in the future of this project”.
Philippe Boucheron, Deputy Director of Life Sciences at Bpifrance Investissement has declared: “BpiFrance is delighted to work with GamaMabs Pharma and to support a truly innovative therapeutic approach for ovarian cancer, a cancer for which, sadly, few new solutions have reached the market recently and for which medical attention is important. Stéphane Degove and Jean-François Prost have the ideal combined experience to give GamaMabs Pharma the best chance of success”.
“We are extremely motivated by the development of this first-in-class antibody and our aim is to launch clinical trials in 2015”, added Stéphane Degove and Jean-François Prost. “In addition to the financial support from key investors in the Health sector, this programme benefits from the R&D expertise of the LFB group”.
The management team at GamaMabs Pharma
Dr Jean-François
Prost, Vice President of R&D and Strategy at GamaMabs Pharma has 30
years of experience in the European pharmaceutical industry. Previously
he led the R&D Departments of Servier, Pierre Fabre and UCB Pharma. Over
the past ten years as Scientific and medical director at LFB, he has
determinedly contributed to the development of EMABling® technology and
to that of two antibodies currently in the clinical development.
Stéphane Degove, Chief Executive Officer of GamaMabs pharma, has 17 years of experience in Finance and Strategy in the pharmaceutical and biotechnology industries. An ESCP Europe graduate, he has worked for Sanofi and was a co-founder of Endotis Pharma specializing in thrombosis and cancer.
About the LFB group
LFB is a
French biopharmaceutical group that develops, manufactures and
commercializes/ markets medication for serious and often rare
pathologies in the following major therapeutic fields: immunology,
intensive care and hemostasis.
The LFB group is number one in
France and number five in the world in plasma-derived medicinal
products. The group is also one of the top European companies in the
development and production of proteins and new generation treatments in
biotechnologies. In 2012, 76.7 million euros were put towards research
and development, for a turnover of 465.7 million euros.
Christian
Béchon is the President of the group, which has 1887 employees.
http://www.lfb.fr
About Bpifrance and InnoBio
Bpifrance’s
equity investments are operated by Bpifrance Investissement. Bpifrance
invests directly or indirectly has a minority party through partner’s
equity, in French companies, PME, ETI and larger companies.
InnoBio
is a 139 million euro FCPR managed by Bpifrance and subscribed by the
FSI (37%) and the key global pharmaceutical companies (Sanofi Aventis,
GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda,
Boehringer-Ingelheim) operating in France.
The main objective of
the fund is to directly invest equity or partial equity in the capital
of firms who provide innovative and technological products and services
in the Health sector.
InnoBio, is made up of a team of investors
specialised in the industry and has to this day made 13 investments of a
total of 65 million euros.
www.bpifrance.fr
About IRDInov
IRDInov
is
an interregional seed fund, launched in late 2012 with the support of
the FNA (National Seed Fund) and managed by CDC Enterprises, IRDI, and
the Midi-Pyrénées and Aquitaine Regions alongside partnerships with
regional banks and industrials.
The investment strategy of the fund is centered on spin-off projects
from public or private research organisms in all innovative and
industrial sectors. IRDInov invests (through several fundraising
rounds), sums ranging from 500K euro to 3 million euros in innovative
companies in seed or start-up stages, located in Aquitaine,
Midi-Pyrénées and Limousin.
The fund, managed by the GIE IRDI, was
granted 25.2 million euros in its first round with an aim to raise an
additional 10 million euros.
About IXO PE
IXO private Equity
is an independent company 100 % held by its management team.
It
manages an asset portfolio in capital-investment of 323M€.
The
funds made out from type FIP/FCPI's public offer represent 155M€. FCPR's
funds signed mainly by institutional rise represent, as for them, 168M€.
Located
in Toulouse, IXO Private Equity invests equity in PME located in the
South of France (south east – south-west)
www.ixope.fr
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130929005017/en/
Contact:
GamaMabs Pharma
Stéphane Degove, +33 1 70 96 00 67
CEO
sdegove@gamamabs.com
Jean-François
Prost, +33 1 70 96 00 68
VP R&D and strategy,
jfprost@gamamabs.com
or
LFB group
Sandrine
Charrières, + 33 1 69 82 72 80
Corporate communications
director
charrieres@lfb.fr
or
IRDInov
Jean-Michel
Petit, Tel : +33 05 81 317 320
jean.michel.petit@irdi.fr
or
IXO
PE
+33 5 34 417 418
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
SES Announces Results of the Annual General Meeting2.4.2026 16:49:00 CEST | Press release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
Andersen Consulting styrker sine kompetencer med tilføjelsen af Lukkap2.4.2026 16:31:00 CEST | Pressemeddelelse
Andersen Consulting tilføjer samarbejdspartneren Lukkap, et konsulenthus med fokus på oplevelsesdrevne kompetencer, der er tilpasset kundernes skiftende behov inden for transformation af medarbejdere, kunder og det digitale område. Lukkap, der blev stiftet i 2009 og har hovedsæde i Spanien, leverer integrerede løsninger, der hjælper organisationer med at transformere, hvordan de betjener kunder, engagerer medarbejdere og frigør værdi gennem adfærdsindsigt og dataanalyse. Virksomhedens tværfaglige tilgang spænder over nytænkning af kunderejsen, effektive programmer for medarbejderoplevelser, talent- og ledelsesudvikling, prædiktiv analyse samt omfattende outplacement- og transitionsydelser. Lukkap arbejder på tværs af sektorer — herunder sundhedsvæsen, medicinalindustri, forbrugsgoder, detailhandel, finans og bankvæsen — for at opbygge menneskecentrerede strategier, der skaber målbare forretningsresultater. "Ved at kombinere vores erfaringsdrevne metode med Andersen Consultings globale
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 16:00:00 CEST | Press release
Low AI fluency, uneven adoption, and marginal productivity gains are limiting enterprise-scale impact According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those
The LYCRA Company Announces Strategic Partnership on Renewable LYCRA® Fiber2.4.2026 15:00:00 CEST | Press release
Agreement with Texhong Advances Sustainable Fiber Applications The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the signing of a strategic partnership agreement with Texhong International Group Limited (“Texhong”), one of the world’s largest suppliers of core-spun cotton textiles. Under the agreement, Texhong will exclusively partner with The LYCRA Company to bring Renewable LYCRA® fiber made with 30 percent plant-based content* to China’s core-spun yarn sector. This collaboration aims to accelerate the adoption of bio-derived spandex across the global apparel and textile industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402505834/en/ The LYCRA Company announced a strategic partnership with Texhong International Group for renewable LYCRA® fiber. Pictured at the signing ceremony held in Shanghai (left to right): Jason Wang,
Brightfin Unifies Brand Following Proven Optics Merger, Delivering a New Standard for Technology Cost Optimization2.4.2026 15:00:00 CEST | Press release
New identity reflects expanded vision to help CIOs “See Clearly. Spend Better.” Brightfin today announced that, following its merger with Proven Optics, the combined company will operate under a single brand: Brightfin. The unified company brings together deep expertise in Technology Expense Management (TEM) and IT Financial Management (ITFM) to help organizations better understand, manage, and reduce total technology spend. Technology spending will exceed $6 Trillion this year, and for most organizations, it remains one of the least understood. CIOs can tell you what they’re spending. Far fewer can tell you whether it’s working. “Over the past several months, we’ve brought these two businesses together around a shared purpose: help enterprise businesses better understand and optimize their technology spend,” said Joel Martins, CEO of Brightfin. “What we are seeing now is a shift. Visibility alone isn’t enough. Teams need to be able to act, tied to real financial outcomes. See Clearly.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum